Financial information

Independency and transparency

Principle of non interference of any funder (public or private) or sponsor in GAMIAN-Europe’s activities
Subscription of EFPIA code of conduct (laid down by statute)

Principle of multi funding: GAMIAN-Europe is not dependent of an unique funder, and it’s activities will never be endangered by the threat of a funder to quit.

Democratic decision making on general policy
•    Yearly General Assembly
•    No financial barrier for full members to attend tehj meetings of the General Assembly
•    Yearly open discussion on activity report of the past year and planning for the coming year.

Financial transparency
•    Yearly financial report, by professional, independent accountant.
•    Audit report by professional auditor presented by the treasurer at annual general assembly.
•    Publication of all financial reports (income and expenses) and balance on website.
•    Full financial report publicly available at commercial court of Brussels

_______________________________________________________

 

2014-2015 

OPERATING  INCOME financial year 2014/2015: 230.492,03 €

GRANTS RECEIVED IN 2015  (calendar year)

Janssen: 40.000 € (= 17,35 %)
Lundbeck: 25.000 € (= 10,84%)
GSK: 25.000 € ( = 10,84%)
Lilly: 4.900 € ( = 2,12%)
Roche: 7.500 € ( = 3,25%)
Shire: 14.900 € ( = 6,46%)
Takeda: 3.000 € ( = 1,30%)
TEVA: 41.973 € ( = 18,20%)

ECNP: 14.900 € ( = 6,46%)

Research grants FP7: 28.600 €  ( =12,40%)

Total industry funding  = 70,45%
Total Non industry funding = 29,55%
Highest industry grant:  =  18,20%

Download:

Audit Report 2015 

Definitive financial report 14-15 20151020

Minutes_GAMIAN-Europe Annual Convention Brussels 2015

2015-2016 

Download: 

Audit Report 2016 

Minutes GAMIAN-Europe Annual Convention Vienna 2016

 

Share on: